U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244380) titled 'Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.' on Nov. 17.
Brief Summary: To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.
Study Start Date: Nov. 28
Study Type: INTERVENTIONAL
Condition:
T Lymphoblastic Leukemia/Lymphoma
Intervention:
BIOLOGICAL: Autologous CD7-targeting CAR T cells
Autologous CD7-targeting CAR T cells, dosage 2*10^6/kg, intravenous injection once
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Published by HT Digital Content Services with permission from Health Daily Diges...